Literature DB >> 2291658

Comparative study of the effects of four cephalosporins against Escherichia coli in vitro and in vivo.

M L van Ogtrop1, H Mattie, H F Guiot, E van Strijen, A M Hazekamp-van Dokkum, R van Furth.   

Abstract

A thigh muscle infection induced with Escherichia coli in irradiated mice was used as a model to compare the in vivo pharmacodynamics of the antibacterial effect of four cephalosporins (i.e., cefepime, ceftriaxone, ceftazidime, and cefoperazone) with the in vitro antibacterial pharmacodynamics of these drugs. The following in vitro pharmacodynamic parameters were determined: the maximum effect as a measure for efficacy, the 50% effective concentration as a parameter for potency, and the slope of the concentration-effect relationship. For analysis of the in vivo antibacterial pharmacodynamics, the same parameters were applied for the dose instead of the concentration. For the detection of a relationship between concentration and antibacterial effect in vivo, we determined the pharmacokinetics of the four cephalosporins in the plasma of mice. The results showed that, in general, there is a direct relationship between the in vivo and in vitro pharmacodynamics of these cephalosporins. The maximum effects of cefepime, ceftazidime, and cefoperazone were approximately similar in vivo and in vitro. The sequence of potency of these drugs was, in descending order, cefepime, ceftazidime, and cefoperazone. Ceftriaxone differed from the other three cephalosporins in that it displayed unexpected in vivo pharmacodynamics. Ceftriaxone was just as efficacious as the other three in vitro, but its maximum effect in vivo was much lower. This relatively low maximum effect of ceftriaxone in vivo was not explained by the pharmacokinetic characteristics of the drug. From the present results it can be concluded that the in vitro efficacy of cephalosporins does not necessarily have a predictive value for the in vivo efficacy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2291658      PMCID: PMC171967          DOI: 10.1128/AAC.34.10.1932

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

Review 1.  Empiric treatment of infection during granulocytopenia: a comprehensive approach.

Authors:  J Klastersky
Journal:  Infection       Date:  1989 Mar-Apr       Impact factor: 3.553

2.  The relation between plasma and tissue concentrations of antibiotics. Description of a method.

Authors:  H Mattie; J J Hoogeterp; J Hermans
Journal:  J Pharmacokinet Biopharm       Date:  1987-04

3.  Cefazolin and cephradine: relationship between antibacterial activity in vitro and in mice experimentally infected with Escherichia coli.

Authors:  M W Kunst; H Mattie
Journal:  J Infect Dis       Date:  1978-04       Impact factor: 5.226

4.  High-pressure liquid chromatographic analysis of BMY-28142 in plasma and urine.

Authors:  R H Barbhaiya; S T Forgue; W C Shyu; E A Papp; K A Pittman
Journal:  Antimicrob Agents Chemother       Date:  1987-01       Impact factor: 5.191

Review 5.  Role of pharmacokinetics in the outcome of infections.

Authors:  G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  1988-03       Impact factor: 5.191

Review 6.  The modelling of drug response.

Authors:  B Whiting; A W Kelman
Journal:  Clin Sci (Lond)       Date:  1980-11       Impact factor: 6.124

7.  The relative potency of amoxycillin and ampicillin in vitro and in vivo.

Authors:  H Mattie; G B van der Voet
Journal:  Scand J Infect Dis       Date:  1981

8.  Cefazolin and cephradine: relationship between serum concentrations and tissue contents in mice.

Authors:  M W Kunst; H Mattie
Journal:  Infection       Date:  1978       Impact factor: 3.553

9.  Experimental infection with Streptococcus pneumoniae in mice: correlation of in vitro activity and pharmacokinetic parameters with in vivo effect for 14 cephalosporins.

Authors:  N Frimodt-Møller; M W Bentzon; V F Thomsen
Journal:  J Infect Dis       Date:  1986-09       Impact factor: 5.226

10.  Postantibiotic leukocyte enhancement: increased susceptibility of bacteria pretreated with antibiotics to activity of leukocytes.

Authors:  P J McDonald; B L Wetherall; H Pruul
Journal:  Rev Infect Dis       Date:  1981 Jan-Feb
View more
  14 in total

1.  Pharmacodynamics of Cefepime Combined with Tazobactam against Clinically Relevant Enterobacteriaceae in a Neutropenic Mouse Thigh Model.

Authors:  Maria J Melchers; Anita C van Mil; Claudia Lagarde; Jan den Hartigh; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

2.  Comparison of the effects of aztreonam and tigemonam against Escherichia coli and Klebsiella pneumoniae in vitro and in vivo.

Authors:  M L van Ogtrop; H Mattie; H F Guiot; E van Strijen; B R Sekh; R van Furth
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

3.  Disposition kinetics, bioavailability and renal clearance of cefepime in calves.

Authors:  M M Ismail
Journal:  Vet Res Commun       Date:  2005-01       Impact factor: 2.459

4.  Modulation of the intestinal flora of mice by parenteral treatment with broad-spectrum cephalosporins.

Authors:  M L van Ogtrop; H F Guiot; H Mattie; R van Furth
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

5.  Pharmacokinetics and penetration of ceftazidime and avibactam into epithelial lining fluid in thigh- and lung-infected mice.

Authors:  Johanna Berkhout; Maria J Melchers; Anita C van Mil; Seyedmojtaba Seyedmousavi; Claudia M Lagarde; Wright W Nichols; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

6.  Efficacy of short-course ceftriaxone therapy for Borrelia burgdorferi infection in C3H mice.

Authors:  Charles Pavia; Mario A Inchiosa; Gary P Wormser
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

7.  Novel rate-area-shape modeling approach to quantify bacterial killing and regrowth for in vitro static time-kill studies.

Authors:  Soon-Ee Cheah; Jian Li; Roger L Nation; Jürgen B Bulitta
Journal:  Antimicrob Agents Chemother       Date:  2014-11-03       Impact factor: 5.191

8.  Correlation between in vitro and in vivo activities of GM 237354, a new sordarin derivative, against Candida albicans in an in vitro pharmacokinetic-pharmacodynamic model and influence of protein binding.

Authors:  P Aviles; C Falcoz; M J Guillén; R San Roman; F Gómez De Las Heras; D Gargallo-Viola
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

9.  Animal pharmacokinetics and interspecies scaling of sordarin derivatives following intravenous administration.

Authors:  P Aviles; A Pateman; R San Roman; M J Guillén; F Gómez De Las Heras; D Gargallo-Viola
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

Review 10.  Cefepime clinical pharmacokinetics.

Authors:  M P Okamoto; R K Nakahiro; A Chin; A Bedikian
Journal:  Clin Pharmacokinet       Date:  1993-08       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.